

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:42:05 ON 29 MAY 2008

=> file caplus medline biosis embase

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 15:42:51 ON 29 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:42:51 ON 29 MAY 2008

FILE 'BIOSIS' ENTERED AT 15:42:51 ON 29 MAY 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:42:51 ON 29 MAY 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s formoterol

L1 5953 FORMOTEROL

=> s steroid

L2 631202 STEROID

=> s inflammatory

L3 978119 INFLAMMATORY

=> s L2 and L3

L4 35237 L2 AND L3

=> s L1 and L4

L5 120 L1 AND L4

=> s L5 and (AY<2002 or PY<2002 or PRY<2002)

'2002' NOT A VALID FIELD CODE

'2002' NOT A VALID FIELD CODE

2 FILES SEARCHED...

'2002' NOT A VALID FIELD CODE

'2002' NOT A VALID FIELD CODE

'2002' NOT A VALID FIELD CODE

'2002' NOT A VALID FIELD CODE

L6 40 L5 AND (AY<2002 OR PY<2002 OR PRY<2002)

=> dup rem L6

PROCESSING COMPLETED FOR L6

L7 40 DUP REM L6 (0 DUPLICATES REMOVED)

=> s water

L8 4384561 WATER

=> s L7 and L8

L9 3 L7 AND L8

=> d 1-3 L9 ibib abs

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:813911 CAPLUS Full-text
DOCUMENT NUMBER: 137:316082
TITLE: Formoterol/steroid bronchodilating
compositions and methods of use thereof
INVENTOR(S): Banerjee, Partha S.; Chaudry, Imitiaz A.
PATENT ASSIGNEE(S): Dey LP, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083113	A2	20021024	WO 2002-US6252	20020301 <--
WO 2002083113	A3	20030320		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20030055026	A1	20030320	US 2001-887496	20010622 <--
CA 2444535	A1	20021024	CA 2002-2444535	20020301 <--
AU 2002250199	A1	20021028	AU 2002-250199	20020301 <--
AU 2002250199	B2	20070726		
EP 1385494	A2	20040204	EP 2002-719098	20020301 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005512944	T	20050512	JP 2002-580917	20020301 <--
US 20020183293	A1	20021205	US 2002-145978	20020513 <--
PRIORITY APPLN. INFO.:			US 2001-284607P	P 20010417 <--
			US 2001-887496	A1 20010622 <--
			WO 2002-US6252	W 20020301

AB Bronchodilating compns. intended for administration as a nebulized aerosol are provided. In certain embodiments, the compns. contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compns. provided herein are also provided. For example, a solution was prepared containing Formoterol fumarate dihydrate 85 µg/mL, budesonide 125 µg/mL, vitamin E TPGS 10 µg/mL, Polyethylene glycol 10 µg/mL, citrate buffer 50mM, sodium chloride 7.5 mg/mL, and water as needed.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:555336 CAPLUS Full-text
DOCUMENT NUMBER: 137:114526
TITLE: A method for the preparation of nanoparticles
INVENTOR(S): Watanabe, Wiwik; Kauppinen, Esko; Ahonen, Petri; Brown, David; Muttonen, Esa
PATENT ASSIGNEE(S): Orion Corporation, Finland

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056866	A1	20020725	WO 2002-FI42	20020118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002229791	A1	20020730	AU 2002-229791	20020118 <--
EP 1351666	A1	20031015	EP 2002-710900	20020118 <--
EP 1351666	B1	20080227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520157	T	20040708	JP 2002-557374	20020118 <--
AT 387185	T	20080315	AT 2002-710900	20020118 <--
US 20040091542	A1	20040513	US 2003-466365	20031211 <--
PRIORITY APPLN. INFO.:			FI 2001-115	A 20010118 <--
			WO 2002-FI42	W 20020118

AB The invention relates to free nano-sized particles of active agents e.g. therapeutic, cosmetic or diagnostic agents, and to a method for the preparation of such particles. The method comprises providing a liquid feed stock comprising an active agent or combination of two or more active agents, atomizing the liquid feed stock, suspending the droplets in a carrier gas, and passing the carrier gas and droplets through a heated tube flow reactor under predetd. residence time and temperature history, and collecting the particles produced. Nano-sized crystalline spherical uncharged particles with narrow aerodynamic particle size distribution and rough surfaces, are obtained. The particles show improved dissoln. rate in-vitro and bioavailability in-vivo, dispersibility and stability. Nanosized beclomethasone dipropionate particles were prepared

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:833060 CAPLUS Full-text

DOCUMENT NUMBER: 135:376741

TITLE: Stable metal ion-lipid powdered pharmaceutical compositions

INVENTOR(S): Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E.

PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001085137	A2	20011115	WO 2001-US14824	20010508 <--
WO 2001085137	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6630169	B1	20031007	US 2000-720536	20001222 <--
CA 2408464	A1	20011115	CA 2001-2408464	20010508 <--
EP 1282405	A2	20030212	EP 2001-933194	20010508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533449	T	20031111	JP 2001-581791	20010508 <--
MX 2002PA11003	A	20040819	MX 2002-PA11003	20021108 <--
AU 2002318867	A1	20030410	AU 2002-318867	20021210 <--
AU 2006200277	A1	20060216	AU 2006-200277	20060123
AU 2006200277	B2	20080410		
AU 2006200768	A1	20060316	AU 2006-200768	20060224 <--
AU 2006236049	A1	20061207	AU 2006-236049	20061115 <--
KR 2008031532	A	20080408	KR 2008-707331	20080326 <--
PRIORITY APPLN. INFO.:			US 2000-568818	A 20000510 <--
			AU 1999-10644	A3 19980929 <--
			WO 1999-US6855	W 19990331 <--
			AU 2001-61246	A3 20010508 <--
			WO 2001-US14824	W 20010508 <--
			KR 2002-715136	A3 20021111
			AU 2002-318867	A3 20021210
			AU 2003-204270	A3 20030520

AB Microparticle compns. comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compns. and methods of treating certain conditions and disease states by administering the microparticle compns. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compns. of the present invention have superior stability to other microparticle compns. resulting in a microparticle composition with longer shelf life and improved dispersibility. The microparticle compns. of the present invention have a transition temperature (T_m) of at least 20° above the recommended storage temperature (T_{st}) for drug delivery. An aqueous preparation was prepared by mixing two prepns., A and B, immediately prior to spray drying. The preparation A was comprised of a fluorocarbon-in-water emulsion in which 26 g perfluorooctyl bromide was dispersed in 33 g water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The preparation B contained 0.162 g CaCl₂·2H₂O and 0.162 g budesonide dissolved/suspended in 4 g water. The resulting microparticle of the sample had a PL-budesonide-CaCl₂·2H₂O weight ratio of about 80:10:10. The mean volume aerodynamic particle size of the dry powder was approx. 4.1 µm.

=> s L1 and water
L10 118 L1 AND WATER

=> s L10 and L2
L11 15 L10 AND L2

```
=> dup rem L11
PROCESSING COMPLETED FOR L11
L12          15 DUP REM L11 (0 DUPLICATES REMOVED)

=> s L12 and (AY<2003 or PY<2003 or PRY<2003)
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
  2 FILES SEARCHED...
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
'2003' NOT A VALID FIELD CODE
L13          6 L12 AND (AY<2003 OR PY<2003 OR PRY<2003)
```

```
=> d 1-6 L13 ibib abs
```

```
L13  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2004:531336  CAPLUS  Full-text
DOCUMENT NUMBER:       141:76760
TITLE:                 Pharmaceutical porous particles comprising lipid
                        carriers
INVENTOR(S):           Harwigsson, Ian
PATENT ASSIGNEE(S):    Adagit, Swed.
SOURCE:                PCT Int. Appl., 58 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054556	A1	20040701	WO 2003-SE1952	20031215 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509216	A1	20040701	CA 2003-2509216	20031215 <--
AU 2003287132	A1	20040709	AU 2003-287132	20031215 <--
EP 1569626	A1	20050907	EP 2003-781201	20031215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006511617	T	20060406	JP 2005-508295	20031215 <--
US 20060002995	A1	20060105	US 2005-149927	20050610 <--
PRIORITY APPLN. INFO.:			SE 2002-3687	A 20021213 <--
			US 2003-457396P	P 20030325
			WO 2003-SE1952	W 20031215
AB The present invention relates to a pharmaceutical, preferably inhalable, porous, free flowing particle to be used in therapeutical applications, optionally comprising a therapeutically active compound or substance, whereby the particle consists of one or more network forming compds., which in diluted solns. self assoc. to large three dimensional structures having a d. of < 0.5 g/cm3. A solution consisting of dipalmitoylphosphatidylcholine 1 g and				

dimyristoylphosphatidylcholine 2 g was mixed with 180 µL water and 300 mL hexane. The total solution was heated until a viscous solution was obtained. The solution was dried to give a product comprising porous low d. particles having a large 3 dimensional network. The powders 0.01 g were mixed with dry particles of formoterol 0.005 g in a vial for inhalation.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:813911 CAPLUS Full-text
DOCUMENT NUMBER: 137:316082
TITLE: Formoterol/steroid bronchodilating compositions and methods of use thereof
INVENTOR(S): Banerjee, Partha S.; Chaudry, Imitiaz A.
PATENT ASSIGNEE(S): Dey LP, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083113	A2	20021024	WO 2002-US6252	20020301 <--
WO 2002083113	A3	20030320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030055026	A1	20030320	US 2001-887496	20010622 <--
CA 2444535	A1	20021024	CA 2002-2444535	20020301 <--
AU 2002250199	A1	20021028	AU 2002-250199	20020301 <--
AU 2002250199	B2	20070726		
EP 1385494	A2	20040204	EP 2002-719098	20020301 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005512944	T	20050512	JP 2002-580917	20020301 <--
US 20020183293	A1	20021205	US 2002-145978	20020513 <--
PRIORITY APPLN. INFO.:				
			US 2001-284607P	P 20010417 <--
			US 2001-887496	A1 20010622 <--
			WO 2002-US6252	W 20020301 <--

AB Bronchodilating compns. intended for administration as a nebulized aerosol are provided. In certain embodiments, the compns. contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compns. provided herein are also provided. For example, a solution was prepared containing Formoterol fumarate dihydrate 85 µg/mL, budesonide 125 µg/mL, vitamin E TPGS 10 µg/mL, Polyethylene glycol 10 µg/mL, citrate buffer 50mM, sodium chloride 7.5 mg/mL, and water as needed.

L13 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:555336 CAPLUS Full-text
 DOCUMENT NUMBER: 137:114526
 TITLE: A method for the preparation of nanoparticles
 INVENTOR(S): Watanabe, Wiwik; Kauppinen, Esko; Ahonen, Petri;
 Brown, David; Muttonen, Esa
 PATENT ASSIGNEE(S): Orion Corporation, Finland
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056866	A1	20020725	WO 2002-FI42	20020118 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002229791	A1	20020730	AU 2002-229791	20020118 <--
EP 1351666	A1	20031015	EP 2002-710900	20020118 <--
EP 1351666	B1	20080227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520157	T	20040708	JP 2002-557374	20020118 <--
AT 387185	T	20080315	AT 2002-710900	20020118 <--
US 20040091542	A1	20040513	US 2003-466365	20031211 <--
PRIORITY APPLN. INFO.:			FI 2001-115	A 20010118 <--
			WO 2002-FI42	W 20020118 <--

AB The invention relates to free nano-sized particles of active agents e.g. therapeutic, cosmetic or diagnostic agents, and to a method for the preparation of such particles. The method comprises providing a liquid feed stock comprising an active agent or combination of two or more active agents, atomizing the liquid feed stock, suspending the droplets in a carrier gas, and passing the carrier gas and droplets through a heated tube flow reactor under predetd. residence time and temperature history, and collecting the particles produced. Nano-sized crystalline spherical uncharged particles with narrow aerodynamic particle size distribution and rough surfaces, are obtained. The particles show improved dissoln. rate in-vitro and bioavailability in-vivo, dispersibility and stability. Nanosized beclomethasone dipropionate particles were prepared

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:833060 CAPLUS Full-text

DOCUMENT NUMBER: 135:376741
 TITLE: Stable metal ion-lipid powdered pharmaceutical compositions
 INVENTOR(S): Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.;
 Weers, Jeffry G.; Tarara, Thomas E.
 PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085137	A2	20011115	WO 2001-US14824	20010508 <--
WO 2001085137	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6630169	B1	20031007	US 2000-720536	20001222 <--
CA 2408464	A1	20011115	CA 2001-2408464	20010508 <--
EP 1282405	A2	20030212	EP 2001-933194	20010508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533449	T	20031111	JP 2001-581791	20010508 <--
MX 2002PA11003	A	20040819	MX 2002-PA11003	20021108 <--
AU 2002318867	A1	20030410	AU 2002-318867	20021210 <--
AU 2006200277	A1	20060216	AU 2006-200277	20060123 <--
AU 2006200277	B2	20080410		
AU 2006200768	A1	20060316	AU 2006-200768	20060224 <--
AU 2006236049	A1	20061207	AU 2006-236049	20061115 <--
KR 2008031532	A	20080408	KR 2008-707331	20080326 <--
PRIORITY APPLN. INFO.:				
			US 2000-568818	A 20000510 <--
			AU 1999-10644	A3 19980929 <--
			WO 1999-US6855	W 19990331 <--
			AU 2001-61246	A3 20010508 <--
			WO 2001-US14824	W 20010508 <--
			KR 2002-715136	A3 20021111 <--
			AU 2002-318867	A3 20021210 <--
			AU 2003-204270	A3 20030520 <--

AB Microparticle compns. comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compns. and methods of treating certain conditions and disease states by administering the microparticle compns. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compns. of the present invention have superior stability to other microparticle compns. resulting in a microparticle composition with longer shelf life and improved dispersibility. The microparticle compns. of the present invention have a transition temperature (T_m) of at least 20° above the recommended storage temperature (T_{st}) for drug delivery. An aqueous preparation was prepared by mixing two prepsns., A and B, immediately prior to spray drying. The preparation A was comprised of a fluorocarbon-in-water emulsion in which 26 g perfluorooctyl bromide was dispersed in 33 g water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The preparation B contained 0.162 g CaCl₂·2H₂O and 0.162 g budesonide dissolved/suspended in 4 g water. The resulting microparticle of the sample had a PL-budesonide-CaCl₂·2H₂O weight ratio of about 80:10:10. The mean volume aerodynamic particle size of the dry powder was approx. 4.1 μm.

ACCESSION NUMBER: 2000:254113 CAPLUS Full-text
 DOCUMENT NUMBER: 132:284231
 TITLE: Storable formulation of active substance
 INVENTOR(S): Hochrainer, Dieter; Zierenberg, Bernd
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: Ger. Offen., 8 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19847970	A1	20000420	DE 1998-19847970	19981017 <--
CA 2345675	A1	20000427	CA 1999-2345675	19991009 <--
CA 2345675	C	20080506		
WO 2000023037	A1	20000427	WO 1999-EP7589	19991009 <--
W: AE, AU, BG, BR, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9963370	A	20000508	AU 1999-63370	19991009 <--
AU 761858	B2	20030612		
BR 9914608	A	20010703	BR 1999-14608	19991009 <--
EP 1119334	A1	20010801	EP 1999-950688	19991009 <--
EP 1119334	B1	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101095	T2	20010821	TR 2001-1095	19991009 <--
HU 2001003888	A2	20020228	HU 2001-3888	19991009 <--
HU 2001003888	A3	20020828		
HU 224244	B1	20050628		
EE 200100225	A	20020815	EE 2001-225	19991009 <--
EE 4514	B1	20050815		
JP 2002527205	T	20020827	JP 2000-576814	19991009 <--
NZ 511646	A	20021126	NZ 1999-511646	19991009 <--
AT 231715	T	20030215	AT 1999-950688	19991009 <--
EP 1291013	A2	20030312	EP 2002-14579	19991009 <--
EP 1291013	A3	20031126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
ES 2187202	T3	20030516	ES 1999-950688	19991009 <--
PT 1119334	T	20030630	PT 1999-950688	19991009 <--
PL 194220	B1	20070531	PL 1999-347365	19991009 <--
EG 23069	A	20040229	EG 1999-1285	19991014 <--
TW 466111	B	20011201	TW 1999-88117882	19991015 <--
IN 2001MN00352	A	20050715	IN 2001-MN352	20010303 <--
BG 105390	A	20011130	BG 2001-105390	20010329 <--
BG 64523	B1	20050630		
NO 2001001830	A	20010618	NO 2001-1830	20010410 <--
NO 321748	B1	20060626		
HR 2001000273	A1	20020630	HR 2001-273	20010412 <--
US 20010032643	A1	20011025	US 2001-871500	20010531 <--
US 6481435	B2	20021119		
US 20030066524	A1	20030410	US 2002-256781	20020927 <--
US 6986346	B2	20060117		
US 20050159441	A1	20050721	US 2005-77681	20050311 <--
US 7040311	B2	20060509		

PRIORITY APPLN. INFO.:

DE 1998-19847968	A	19981017 <--
DE 1998-19847970	A	19981017 <--
US 1998-112380	P	19981214 <--
US 1998-112380P	P	19981214 <--
EP 1999-950688	A3	19991009 <--
WO 1999-EP7589	W	19991009 <--
US 1999-416476	A1	19991012 <--
US 2001-871500	A1	20010531 <--
US 2002-256781	A1	20020927 <--

AB A storage-stable formulation of an active substance in the form of a concentrated solution or suspension in an atomizer or cartridge is provided for use in inhalers. The concentrate is diluted with H₂O or solvent immediately before the 1st use of the composition. Stability of suspended particles of the active substance in the formulation is enhanced by addition of an alkali metal or ammonium chloride or salt of an organic acid. The active substance may be a β -mimetic, anticholinergic, or antiallergic drug, platelet-activating factor antagonist, leukotriene antagonist, and/or steroid. Thus, a suspension of 5 mg formoterol (particle size 5 μ m) in 0.015 mL water was adjusted to pH 5.0 with fumaric acid for storage. This suspension was diluted with 4.5 mL H₂O/EtOH (1:1) containing benzalkonium chloride 0.45 and Na EDTA 2.25 mg, adjusted to pH 5.0 with HCl, for inhalation.

L13 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:133202 CAPLUS Full-text

DOCUMENT NUMBER: 130:200925

TITLE: Finely divided pharmaceutical particles for inhalation

INVENTOR(S): Briggner, Lars-Erik; Bystrom, Katarina; Jakupovic, Edib; Trofast, Eva; Trofast, Jan

PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.

SOURCE: U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 459,660.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 5874063	A	19990223	US 1996-606655	19960226 <--
AU 9215347	A	19921117	AU 1992-15347	19920324 <--
AU 662519	B2	19950907		
EP 580648	A1	19940202	EP 1992-907877	19920324 <--
EP 580648	B1	19960508		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06506454	T	19940721	JP 1992-507195	19920324 <--
JP 3400999	B2	20030428		
EP 680752	A2	19951108	EP 1995-111178	19920324 <--
EP 680752	A3	19951122		
EP 680752	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
PL 168232	B1	19960131	PL 1992-301008	19920324 <--
RU 2112507	C1	19980610	RU 1993-58260	19920324 <--
SK 280310	B6	19991108	SK 1993-1088	19920324 <--
CZ 286936	B6	20000816	CZ 1993-2116	19920324 <--
JP 2003155228	A	20030527	JP 2002-347368	19920324 <--
NO 9303575	A	19931006	NO 1993-3575	19931006 <--
NO 311867	B1	20020211		
FI 105388	B1	20000815	FI 1993-4429	19931008 <--
US 5709884	A	19980120	US 1995-379471	19950130 <--

US 5637620	A	19970610	US 1995-459660	19950602 <--
US 5562923	A	19961008	US 1995-479494	19950607 <--
PRIORITY APPLN. INFO.:			SE 1991-1090	A 19910411 <--
			SE 1993-2777	A 19930827 <--
			US 1993-129204	B1 19931025 <--
			US 1995-379471	B3 19950130 <--
			US 1995-459660	A2 19950602 <--
			US 1995-479494	A2 19950607 <--
			SE 1996-141	A 19960116 <--
			CS 1993-2116	A 19920324 <--
			EP 1992-907877	A3 19920324 <--
			JP 1992-507195	A3 19920324 <--
			WO 1992-SE186	A 19920324 <--
			WO 1994-SE780	W 19940825 <--

AB There are described finely divided particles of a pharmaceutical substance, wherein the substance when submitted to water vapor gives off heat of less than 1.2 J per g, processes for their production and pharmaceutical formulations containing them. An example is given of salbutamol sulfate (25%) and lactose (75%) conditioned with water at relative humidity 55-65%, nonconditioned micronized substance mixture (5-8 J/g) and conditioned micronized mixture (<0.5 J/g).

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
57.56	57.77

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.20	-7.20

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:50:12 ON 29 MAY 2008